礼来:减肥药Orforglipron在3期临床试验中达到主要终点

老虎资讯综合
17 Apr

周四,礼来盘前直线拉升,截至发稿大涨超13%,公司称减肥药Orforglipron在3期临床试验中达到主要终点。参与者在最高剂量下平均减掉16磅。

Orforglipron是第一个口服小分子胰高血糖素样肽-1(GLP-1)受体激动剂,无饮食和水限制。如果获得批准,该公司对其在全球推出orforglipron而不受供应限制的能力充满信心。这将进一步推动礼来减少2型糖尿病等慢性病的使命,预计到2050年,预计2型糖尿病将影响大约7.6亿成年人。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10